Drugs.com - Clinical Trials Clinical trial news from Drugs.com. Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
- NIH Initiative to Systematically Investigate and Establish Function of Every Human Geneon September 27, 2022 at 10:09 pm
September 27, 2022 -- The National Institutes of Health is launching a program to better understand the function of every human gene and generate a catalog of the molecular and cellular consequences of inactivating each gene. The Molecular...
- Study Confirms Link Between COVID-19 Vaccination and Temporary Increase in Menstrual Cycle Lengthon September 27, 2022 at 10:09 pm
September 27, 2022 -- A large international study has confirmed the findings of a previous U.S. study that linked COVID-19 vaccination with an average increase in menstrual cycle length of less than one day. The increase was not associated with any...
- First approval of TAAV synthetic DNA material for use in clinical trialon September 27, 2022 at 5:09 pm
SAN SEBASTIAN, Spain, Sept. 27, 2022. TAAV Biomanufacturing Solutions, SL (TAAV) announced today the anticipated first use in a clinical trial of company-manufactured doggybone DNA (dbDNA)1, a precisely engineered synthetic DNA material....
- Prenatal Steroid Treatment May Improve Survival, Reduce Complications for Extremely Preterm Infantson September 26, 2022 at 11:09 pm
September 26, 2022 -- Steroid treatment before birth appears to improve survival and reduce complications among extremely preterm infants, according to a study funded by the National Institutes of Health. Antenatal steroid therapy, given to women at...
- Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengueon September 26, 2022 at 10:09 pm
Dengue is the most prevalent mosquito-borne viral disease; endemic to 100 countries worldwide, with more than half the world’s populations at-risk AT-752 is a novel, orally administered, direct-acting antiviral in Phase 2 development for...
- Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Ageon September 26, 2022 at 9:09 pm
NEW YORK & MAINZ, Germany--(BUSINESS WIRE) September 26, 2022 -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA)...
- Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraineon September 26, 2022 at 7:09 pm
LEXINGTON, Mass., Sept. 26, 2022. Pulmatrix, Inc., a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE technology, today announced that all subjects have completed...
- Artivion Follows Recommendation to Stop PROACT Xa Clinical Trialon September 23, 2022 at 7:09 pm
ATLANTA, Sept. 23, 2022 -- Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to determine if patients...
- A Healthy Lifestyle May Help Former Smokers Lower Their Risk of Death From All Causeson September 22, 2022 at 10:09 pm
September 22, 2022 -- Former smokers who stick to a healthy lifestyle have a lower risk of dying from all causes than those who don’t engage in healthy habits, according to a new study by researchers at the National Cancer Institute (NCI),...
- People Science and Sen-Jam Pharmaceutical partner to develop people-forward tools to study inflammation, pain, and opioid withdrawal symptoms in the real worldon September 22, 2022 at 7:09 pm
LOS ANGELES and HUNTINGTON, N.Y., Sept. 22, 2022. People Science, a direct-to-consumer scientific research company providing a scaled R&D platform for alternative medicines, and Sen-Jam Pharmaceutical, a drug development company creating novel...
- Two Popular Diabetes Drugs Outperformed Others in Large Clinical Trialon September 21, 2022 at 10:09 pm
September 21, 2022 -- In a large clinical trial that directly compared four drugs commonly used to treat type 2 diabetes, researchers found that insulin glargine and liraglutide performed the best of four medications approved by the U.S. Food and...
- Open Label Safety Study Shows Improved Sleep for Children With ADHD After One Month of Azstaryson September 21, 2022 at 8:09 pm
BOSTON, Sept. 21, 2022. Corium, Inc., a fully integrated biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced publication of a poster,...
- The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALSon September 21, 2022 at 4:09 am
Publication includes the Phase 3 VALOR SOD1-ALS trial and its open-label-extension study, underscoring the importance of these longer-term data 12-month data show earlier initiation of tofersen slowed decline across critical measures of function...
- NIH-Funded Study Shows Sound Sleep Supports Immune Functionon September 21, 2022 at 4:09 am
Adults who cut back on sleep for six weeks had increased markers of inflammation. September 21, 2022 -- Getting a consistent good night’s sleep supports normal production and programming of hematopoietic stem cells, a building block of...
- Heart Medication Shows Potential as Treatment for Alcohol Use Disorderon September 20, 2022 at 11:09 pm
September 20, 2022 -- A medication for heart problems and high blood pressure may also be effective for treating alcohol use disorder, according to a new study by researchers at the National Institutes of Health and their colleagues. The study...
- Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infectionon September 20, 2022 at 10:09 pm
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir Monthly oral islatravir development for pre-exposure prophylaxis...
- Xpira Pharmaceuticals Inc. Receives FDA Approval For Psilocybin Trial IND Applicationon September 20, 2022 at 7:09 pm
TORONTO, Sept. 20, 2022. Xpira Pharmaceuticals ("Xpira" or "the Company"), a leading developer of next-generation psychedelic medicines for the treatment of eating disorders, is pleased to announce has obtained approval from the United States Food...
- Publication of Adlarity Clinical Trial Data: Drug Exposure Equivalent to Oral Donepezil With Favorable GI Side Effect Profileon September 19, 2022 at 7:09 pm
BOSTON, Sept. 19, 2022. Corium, Inc., a fully-integrated biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced publication of its phase 1 healthy volunteer study results...
- Biogen and Sage Therapeutics Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranoloneon September 19, 2022 at 1:09 am
Cambridge, Mass. – Sept. 19, 2022 – Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day...
- Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDAon September 19, 2022 at 1:09 am
September 19, 2022 - Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or...